Skip to content
HowShorted

Perspective Therapeutics, Inc. short interest in 2018

In 2018, Perspective Therapeutics, Inc.'s disclosed short interest ran from 0.21% of shares outstanding on 12 Jan 2018 to 1.65% on 31 Dec 2018, a change of +1.44 percentage points. The year's high was 1.65% on 31 Dec 2018 and its low 0.07% on 15 Mar 2018, averaging 0.69% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.76 days on 30 Nov 2018. Full history: Perspective Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Perspective Therapeutics, Inc. in 2018

2018 in figures

Start of year
0.21% (12 Jan 2018)
End of year
1.65% (31 Dec 2018)
Change
+1.44 pp
High
1.65% (31 Dec 2018)
Low
0.07% (15 Mar 2018)
Average
0.69%
Highest days to cover
9.76 (30 Nov 2018)
SEC filings marked
10

Every report in 2018

Perspective Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20180.21%1.00
31 Jan 20180.11%1.00results (8-K)
15 Feb 20180.12%1.00results (8-K), 10-Q filed
28 Feb 20180.10%1.00
15 Mar 20180.07%1.00
29 Mar 20180.10%1.00
13 Apr 20180.11%1.00
30 Apr 20180.09%1.00results (8-K)
15 May 20180.28%1.00results (8-K), 10-Q filed
31 May 20180.18%1.00
29 Jun 20180.17%1.00
28 Sep 20181.43%1.23results (8-K), 10-K filed
15 Oct 20181.56%2.75
31 Oct 20181.60%4.74
15 Nov 20181.51%4.38results (8-K), 10-Q filed
30 Nov 20181.58%9.76
14 Dec 20181.52%9.46
31 Dec 20181.65%3.93

See also: Perspective Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.